Broome Oncology
Latest Clinical News

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (09-21-2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC)... Continue Reading

Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer (09-20-2017)

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (09-19-2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates... Continue Reading

NSAIDs Decrease Risk of Colorectal Cancer (09-18-2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively... Continue Reading

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer (09-18-2017)

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach... Continue Reading

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (09-13-2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (09-11-2017)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (09-11-2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

CancerConnect On Line Support Community Available for Cancer Patients and Caregivers Impacted by Hurricane Irma (09-8-2017)

CancerConnect is a specialized social network for patients with cancer and their caregivers. All the members of the CancerConnect community are hoping for the best for everyone in Florida facing the coming wrath of Hurricane Irma. We are especially concerned... Continue Reading

Pass it On: It’s National Thyroid Awareness Month (09-8-2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer happens when cells in the thyroid grow out of control.... Continue Reading

Two Advances in Prostate Cancers You Might Not Know About (09-8-2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Liquid Biopsies Find Distinct Genomic Profiles in Most Patients with Carcinoma of Unknown Primary (09-7-2017)

New research suggests that a simple blood test to evaluate circulating tumor DNA (ctDNA) can correctly identify distinct genomic profiles with potentially treatable targetable alterations in patients with carcinoma of unknown primary (CUP).1 Identifying... Continue Reading

Next Page »